Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXECUTIVE: Exenatide in CABG patients
NCT01373216Phase 3Completed
- Sponsor
- Charles University
- Start
- Jun 2011
- Primary completion
- May 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in coronary artery disease (CAD), left ventricular systolic dysfunction (LVSD), sponsored by Charles University. Started Jun 2011; status: completed.
02
Drugs
exenatide
03
Conditions
coronary artery disease (CAD)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on NCT01373216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01373216.